Abstract: Embodiments of the present invention provides an apparatus containing a device communicably coupled to two electrodes that may be positioned on a body of a subject for obtaining 12 leads or 18 leads electrocardiogram. The two electrodes may obtain signal parameters such as arm leads (I, II, III, AVR AVL and AVF) and left chest leads (V1, V2, V3, V4, V5, V6) and right chest leads (V1R, V2R, V3R, V4R, V5R, V6R). The signal parameters may be detected and collected by the device for processing thereof and thus obtain 12 leads or 18 leads electrocardiogram that may be transmitted to a health care provider for seeking health assistance based on the transmitted electrocardiogram. Further, a method for obtaining the electrocardiogram using two electrodes is also provided.

Abstract: Embodiments of the present invention provides an apparatus containing a device communicably coupled to two electrodes that may be positioned on a body of a subject for obtaining 12 leads or 18 leads electrocardiogram. The two electrodes may obtain signal parameters such as arm leads (I, II, III, AVR AVL and AVF) and left chest leads (V1, V2, V3, V4, V5, V6) and right chest leads (V1R, V2R, V3R, V4R, V5R, V6R). The signal parameters may be detected and collected by the device for processing thereof and thus obtain 12 leads or 18 leads electrocardiogram that may be transmitted to a health care provider for seeking health assistance based on the transmitted electrocardiogram. Further, a method for obtaining the electrocardiogram using two electrodes is also provided.

Abstract: The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present invention also includes the use of the controlled-release composition, either alone or in combination with at least one additional active agent, for reduction of vascular inflammation marker and treatment of diseases, conditions, and/or symptoms associated with systemic and/or vascular inflammation in a patient. Furthermore, the present invention provides a process of making granules comprising N-acetylcysteine, or a salt, solvate, prodrug, and/or analog thereof.

Abstract: The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present invention also includes the use of the controlled-release composition, either alone or in combination with at least one additional active agent, for reduction of vascular inflammation marker and treatment of diseases, conditions, and/or symptoms associated with systemic and/or vascular inflammation in a patient. Furthermore, the present invention provides a process of making granules comprising N-acetylcysteine, or a salt, solvate, prodrug, and/or analog thereof.

Abstract: The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present invention also includes the use of the controlled-release composition, either alone or in combination with at least one additional active agent, for reduction of vascular inflammation marker and treatment of diseases, conditions, and/or symptoms associated with systemic and/or vascular inflammation in a patient. Furthermore, the present invention provides a process of making granules comprising N-acetylcysteine, or a salt, solvate, prodrug, and/or analog thereof.

Abstract: Apparatuses for assisting motion of vehicles are disclosed here. Embodiments of the present disclosure include an apparatus comprising, a charge-storage unit, an electromotor coupled to the charge-storage unit, wherein, at least a portion of the power supplied to the electromotor is supplied by the charge-storage unit. The apparatus may further include, a wheel powered by the electromotor to rotate in a plane about an axis, a housing, and a handle coupled to the housing, the handle being physically configured to, when, in operation, couple to an external entity to whom motion assistance is to be provided. The external entity may be a vehicle (e.g., a motor vehicle although other objects may be connected.

Abstract: Apparatuses for assisting motion of vehicles are disclosed here. Embodiments of the present disclosure include an apparatus comprising, a charge-storage unit, an electromotor coupled to the charge-storage unit, wherein, at least a portion of the power supplied to the electromotor is supplied by the charge-storage unit. The apparatus may further include, a wheel powered by the electromotor to rotate in a plane about an axis, a housing, and a handle coupled to the housing, the handle being physically configured to, when, in operation, couple to an external entity to whom motion assistance is to be provided. The external entity may be a vehicle (e.g., a motor vehicle although other objects may be connected.

Abstract: Apparatuses for assisting motion of vehicles are disclosed here. Embodiments of the present disclosure include an apparatus comprising, a charge-storage unit, an electromotor coupled to the charge-storage unit, wherein, at least a portion of the power supplied to the electromotor is supplied by the charge-storage unit. The apparatus may further include, a movable portion powered by the electromotor, a housing coupled to the electromotor, and a handle coupled to the housing, the handle being physically configured to, when, in operation, couple to an external entity to whom motion assistance is to be provided. The external entity may be a vehicle although other objects may be used.

Abstract: A composition and method for inhibiting adrenal enzyme synthesis in a user in order to improve glucose tolerance, reduce obesity, reduce diabetes, reduce hypertension and reduce atherosclerosis. The preferred active ingredient is trilostane which is combined with a suitable carrier which acts as an adrenal enzyme inhibitor and is thus useful for treating diabetes mellitus, hypertension, obesity and atherosclerosis.

Abstract: A device and method for employing it for conducting aerobic abdominal flexion exercise. A resistance is applied to the thigh portion of the legs of the user such that as the user's legs are drawn to the user's torso, the user experiences resistance using such motion that user's legs move away from the user's torso, no resistance is applied to said movement.

Abstract: A method of inhibiting adrenal enzyme synthesis in a user in order to improve glucose tolerance, reduce obesity, reduce diabetes, reduce hypertension and reduce atherosclerosis. The preferred active ingredient is the adrenal enzyme inhibitor trilostane or epostane combined with a suitable sustained release carrier which acts as an adrenal enzyme inhibitor and is thus useful for treating diabetes mellitus, hypertension, obesity and atherosclerosis.